Clinical Trial Detail

NCT ID NCT02784171
Title Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

malignant pleural mesothelioma

Therapies

Cisplatin + Pemetrexed Disodium

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.